VBI Vaccines appoints Dr. Vaughn Himes to its Board of Directors

– USA, MA –  VBI Vaccines Inc. (Nasdaq: VBIV), a biopharmaceutical company, today announced the appointment of Dr. Vaughn Himes (Ph.D.) to its Board of Directors, bringing 30+-year successful track record in biotechnology strategic direction and change management, driving value creation and growth at both small and large biopharmaceutical companies.

“Vaughn brings extensive CMC (chemistry, manufacturing, and controls), product development, quality, and strategic business transformation expertise to VBI. Vaughn has developed and delivered CMC strategies in support of seven new commercial launches valued at more than $2 billion, in addition to driving key operational efforts and corporate development deals valued at more than $1.5 billion,” said CEO, Jeff Baxter.

“VBI is uniquely positioned among its peer group with a commercial product, a fully owned GMP (Good Manufacturing Practice) facility, and a proprietary technology platform with promising and diversified development-stage candidates,” said Dr. Himes. “I look forward to working with my fellow board members and with the VBI team as they endeavor to make a meaningful difference in the fight against hepatitis B and other public health and medical challenges.”

About Dr. Vaughn B. Himes

His industry experience includes nearly 15 years at Seagen, where he is currently CTO and leads the manufacturing, supply chain, process sciences, and quality functions. During his tenure at Seagen, Dr. Himes has helped lead the transition from a research and development-stage company through the successful commercial launch of its first four commercially marketed products and has played critical roles in Seagen’s M&A activity leading to the recent announcement of Pfizer’s intent to acquire the company. Before joining Seagen in 2009, Dr. Himes spent 20 years in leadership roles overseeing CMC, manufacturing, supply chain and logistics, quality control, process development, and product development operations at ZymoGenetics Corporation (acquired by Bristol Myers Squibb), Corixa Corporation (acquired by GlaxoSmithKline), Targeted Genetics Corporation, Genovo Inc., and Wyeth-Lederle Vaccines.

Dr. Himes holds a Ph.D. in Chemical Engineering from the University of Minnesota and a B.A. in Chemistry from Pomona College. He also serves as a director on the Board for Achieve Life Sciences, Inc.

About VBI Vaccines Inc.

VBI Vaccines Inc. is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Through its innovative approach to virus-like particles, including a proprietary enveloped VLP platform technology, VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus, as well as aggressive cancers including glioblastoma. VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.

Source: https://www.vbivaccines.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.